World's Best Scientists 2026 revealed!
Sumanta K. Pal

Sumanta K. Pal

D-Index & Metrics

Medicine

D-Index
95
Citations
36591
World Ranking
9994
National Ranking
5144

Overview

Sumanta K. Pal is a researcher affiliated with City of Hope in the United States, with a primary focus on medicine and related biomedical fields. Their work spans several areas within oncology and molecular biology, building a significant portfolio of publications and collaborations.

The main fields of study associated with Sumanta K. Pal include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their research delves into multiple subfields, such as:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Surgery
  • Molecular Biology
  • Cancer Research

Sumanta K. Pal's work addresses key topics including:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Bladder and Urothelial Cancer Treatments
  • Renal and related cancers
  • Economic and Financial Impacts of Cancer
  • Urinary and Genital Oncology Studies

Their recent papers illustrate active engagement with clinical oncology and cancer treatment research. Selected publications include:

  • "Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology" (2020), published in Journal of the National Comprehensive Cancer Network
  • "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial" (2020), published in Nature Medicine
  • "Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma" (2020), published in Annals of Oncology
  • "Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial" (2022), published in Nature Medicine
  • "A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial" (2021), published in The Lancet

Frequent co-authors collaborating with Sumanta K. Pal include:

  • Nazlı Dizman
  • Toni K. Choueiri
  • Luís Meza
  • Alex Chehrazi-Raffle
  • Tanya B. Dorff

The most common venues where Sumanta K. Pal publishes work are:

  • Journal of Clinical Oncology
  • The Oncologist
  • Annals of Oncology
  • Clinical Genitourinary Cancer
  • European Urology

Best Publications

  • Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

    Padmanee Sharma;Margitta M. Retz;Arlene Siefker-Radtke;Ari D. Baron

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck

  • Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.

    Saro H. Armenian;Lanfang Xu;Bonnie Ky;Canlan Sun

  • Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

    Hans J. Hammers;Elizabeth R. Plimack;Jeffrey R. Infante;Brian I. Rini

  • Bladder cancer. Clinical practice guidelines in oncology.

    Peter E. Clark;Neeraj Agarwal;Matthew C. Biagioli;Mario A. Eisenberger

  • The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

    Jenny J. Ko;Wanling Xie;Nils Kroeger;Jae lyun Lee

  • Triple negative breast cancer: unmet medical needs.

    Sumanta Kumar Pal;Barrett H. Childs;Mark Pegram

  • Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

    Robert J. Motzer;Paul B. Robbins;Thomas Powles;Laurence Albiges

  • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

    T.K. Choueiri;R.J. Motzer;B.I. Rini;J. Haanen

  • Bladder cancer, version 5.2017: Clinical practice guidelines in oncology

    Philippe E. Spiess;Neeraj Agarwal;Rick Bangs;Stephen A. Boorjian

  • Evaluating the older patient with cancer: understanding frailty and the geriatric assessment.

    Sumanta Kumar Pal;Vani Katheria;Arti Hurria

  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

    Asim Amin;Elizabeth R. Plimack;Jeffrey R. Infante;Marc S. Ernstoff

  • Impact of age, sex, and comorbidity on cancer therapy and disease progression.

    Sumanta Kumar Pal;Arti Hurria

  • Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

    Nils Kroeger;Wanling Xie;Jae Lyn Lee;Georg A. Bjarnason

  • Akt inhibitors in clinical development for the treatment of cancer

    Sumanta Kumar Pal;Karen Reckamp;Hua Yu;Robert A Figlin

  • S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites

    Jiehui Deng;Yong Liu;Heehyoung Lee;Andreas Herrmann

  • Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

    Rana R. McKay;Nils Kroeger;Nils Kroeger;Wanling Xie;Jae Lyun Lee

  • Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study

    Nawar Hanna;Maxine Sun;Christian P. Meyer;Paul L. Nguyen

Frequent Co-Authors

Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Hua Yu
Hua Yu City Of Hope National Medical Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Thomas Powles
Thomas Powles Queen Mary University of London
Elizabeth R. Plimack
Elizabeth R. Plimack Fox Chase Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Cora N. Sternberg
Cora N. Sternberg Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have more opportunities than ever to advance their careers through online education. For those looking outside the traditional MD route, related health degrees and certifications can open doors to in-demand roles in healthcare.

Pharmacists remain essential to patient care. Those interested can now access online pharmacy schools offering affordable Doctorate in Pharmacy programs, ideal for busy students or working adults. Similarly, the demand for Nurse Practitioners continues to rise. If you’re considering this path, there are affordable online fnp programs that let you balance study with life responsibilities.

Medical billing and coding are vital to quality healthcare administration. Anyone looking to start a career in this field can find respected medical billing and coding certification online programs. If you are still in high school or just starting to explore healthcare pathways, check out the best online schools for high school students with strong health information management tracks.

With these flexible online options, a rewarding healthcare career could be within reach—no matter your educational background or current stage in life.

Best Scientists Citing Sumanta K. Pal

Trending Scientists

Recently Published Articles